January 16, 2025

Extent and Impact of Primary MMRD in Gliomas Among Children and AYAs

In a cohort study reported in The Lancet Oncology, Negm et al found that primary mismatch repair deficiency (MMRD) was associated with poor outcomes in children, adolescents, and young adults with gli...

The ASCO Post

March 28, 2024

Eflornithine for Adult and Pediatric Patients With High-Risk Neuroblastoma

On December 13, 2023, eflornithine (Iwilfin), an ornithine decarboxylase inhibitor, was approved for adult and pediatric patients with high-risk neuroblastoma with at least a partial response to prior...

The ASCO Post

May 05, 2023

Limited Surgery Plus Proton Therapy in Pediatric and Adolescent Patients With Craniopharyngioma

In a phase II trial (RT2CR) reported in The Lancet Oncology, Thomas E. Merchant, DO, and colleagues found that limited surgery plus proton therapy was associated with a high rate of disease control an...

The ASCO Post

September 15, 2023

Dana-Farber Research Publication 09.15.2023

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.

Dana-Farber

February 08, 2023

Imaging Gets Boost From AI

Two very different populations are the latest to benefit from collaborations with the Biomedical Imaging Research Institute at Cedars-Sinai: children with a cancer predisposition syndrome called neurofibromatosis and men with prostate cancer.

Cedars-Sinai Pulse

June 25, 2024

Tovorafenib in Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

U.S. FDA accelerates approval for tovorafenib (Ojemda) to treat pediatric low-grade glioma harboring a BRAF fusion or rearrangement or BRAF V600 mutation, providing a promising therapeutic option for these patients. Learn more at (source).

The ASCO Post

January 24, 2023

More Than 120 Dana-Farber Affiliated Faculty Named as 2023 Top Doctors in Boston Magazine

Boston magazine has named more than 120 physicians affiliated with Dana-Farber Cancer Institute to its annual "Top Doctors" guide.

Dana-Farber

January 26, 2023

Faculty Publications: Jan. 19 - Jan. 26

This week’s edition of Faculty Publications includes Cedars-Sinai studies that were published Jan.19 - Jan. 26.

Cedars-Sinai Pulse

August 08, 2023

Preoperative Chemoradiation With or Without Pazopanib in Nonrhabdomyosarcoma Soft-Tissue Sarcoma

As reported in the Journal of Clinical Oncology by Aaron R. Weiss, DO, and colleagues, follow-up in the Children’s Oncology Group/NRG Oncology phase II ARST1321 trial showed no differences in survival...

The ASCO Post